# ANTIBODIES ONLINE

# Datasheet for ABIN357144 anti-SIGLEC5 antibody (C-Term)

Image



Go to Product page

#### Overview

1

Quantity:	0.4 mL	
Target:	SIGLEC5	
Binding Specificity:	C-Term	
Reactivity:	Human, Mouse	
Host:	Rabbit	
Clonality:	Polyclonal	
Conjugate:	This SIGLEC5 antibody is un-conjugated	
Application:	Western Blotting (WB), Enzyme Immunoassay (EIA)	
Product Details		
Immunogen:	This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide	
	selected from the C-terminal region of human SIGLEC5.	
Isotype:	Ig Fraction	
Specificity:	This antibody detects SIGLEC5 at C-term.	
Purification:	Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS	

## Target Details

Target:	SIGLEC5
Alternative Name:	CD170 / SIGLEC5 (SIGLEC5 Products)

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 1/3 | Product datasheet for ABIN357144 | 07/26/2024 | Copyright antibodies-online. All rights reserved.

surface. Most SIGLECs have one or more cytoplaamic immune receptor tytosine-based inhibitory motifs (ITIM). SIGLECs are typically expressed on cells of the innate immune system with the exception of the B-cell expressed SIGLEC6. Sequence analysis predicted that the 697-amino acid SIGLEC10 protein contains a signal peptide, an N-terminal V-set Ig-like domain and tour C2-set Ig-like domains, five potential N-linked glycosylation sites, a transmembrane regior and a 126-residue cytoplasmic tail with 3 putative ITIMs. Northern blot analysis detected a major 30 Ab SIGLEC10 transcript, with highest levels in spleen, lymph node, blood leukocytes, and appendix. Little or no expression was observed in pancreas, thyroid, and testis. Flow cytometric analysis demonstrated eosinophi-specific expression of SIGLEC10, but at a lower level than that of SIGLIC08. Expression was also detected on monocytes and a CD16-positive/CD66-negative natural killer-like hymphocyte population. After sialidase treatment, which is necessary for unmasking the sialic acid-binding site on SIGLECs interacting with cell surface sialic acids, cells expression of a 100- to 120-kD monomeric protein, higher than the predicte molecular mass, suggesting that SIGLEC10 bund to red blood cells. Immunoprecipitation analysis indicated expression of a 100- to 120-kD monomeric protein, higher than the predicte molecular mass, suggesting that SIGLEC10 is glycosylated.Synonyms: CD33 antigen-like 2, CD3312, OB-binding protein 2, OBBP2, Obesity-binding protein 2, Sialic acid-binding Ig-like lecti 5, Siglec-5     Molecular Weight:   60715 Da     Gene ID:   8778, 5874     UniProt.   O15389     Application Notes:   ELISA 11,000. Western biot 1:100-1: 500. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user. <th>Target Details</th> <th></th>	Target Details	
Gene ID:   8778, 5874     UniProt:   015389     Application Details   ELISA 1: 1,000. Western blot 1: 100 - 1: 500. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.     Restrictions:   For Research Use only     Handling   Liquid     Concentration:   0.25 mg/mL	Target Details Background:	surface. Most SIGLECs have one or more cytoplasmic immune receptor tyrosine-based inhibitory motifs (ITIM). SIGLECs are typically expressed on cells of the innate immune system, with the exception of the B-cell expressed SIGLEC6. Sequence analysis predicted that the 697-amino acid SIGLEC10 protein contains a signal peptide, an N-terminal V-set Ig-like domain and four C2-set Ig-like domains, five potential N-linked glycosylation sites, a transmembrane region, and a 126-residue cytoplasmic tail with 3 putative ITIMs. Northern blot analysis detected a major 3.0-kb SIGLEC10 transcript, with highest levels in spleen, lymph node, blood leukocytes, and appendix. Little or no expression was observed in pancreas, thyroid, and testis. Flow cytometric analysis demonstrated eosinophil-specific expression of SIGLEC10, but at a lower level than that of SIGLEC8. Expression was also detected on monocytes and a CD16-positive/CD56-negative natural killer-like lymphocyte population. After sialidase treatment, which is necessary for unmasking the sialic acid-binding site on SIGLECs interacting with cell surface sialic acids, cells expression of a 100- to 120-kD monomeric protein, higher than the predicted molecular mass, suggesting that SIGLEC10 is glycosylated. Synonyms: CD33 antigen-like 2, CD33L2, OB-binding protein 2, OBBP2, Obesity-binding protein 2, Sialic acid-binding Ig-like lectin
UniProt:   015389     Application Details   ELISA 1: 1,000. Western blot 1: 100 - 1: 500. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.     Restrictions:   For Research Use only     Handling   Iuquid     Concentration:   0.25 mg/mL	Molecular Weight:	60715 Da
Application Details     Application Notes:   ELISA 1: 1,000. Western blot 1: 100 - 1: 500. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.     Restrictions:   For Research Use only     Handling   Iuquid     Concentration:   0.25 mg/mL	Gene ID:	8778, 5874
Application Notes:   ELISA 1: 1,000. Western blot 1: 100 - 1: 500. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.     Restrictions:   For Research Use only     Handling   Iuquid     Concentration:   0.25 mg/mL	UniProt:	015389
Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.Restrictions:For Research Use onlyHandlingIuidFormat:LiquidConcentration:0.25 mg/mL	Application Details	
Handling   Format: Liquid   Concentration: 0.25 mg/mL	Application Notes:	Other applications not tested.
Format: Liquid   Concentration: 0.25 mg/mL	Restrictions:	For Research Use only
Concentration: 0.25 mg/mL	Handling	
	Format:	Liquid
Buffer: PBS with 0.09 % (W/V) sodium azide	Concentration:	0.25 mg/mL
	Buffer:	PBS with 0.09 % (W/V) sodium azide

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 2/3 | Product datasheet for ABIN357144 | 07/26/2024 | Copyright antibodies-online. All rights reserved.

1.1		1.
$\square$	lond	lina
	land	шu

Preservative:	Sodium azide
Precaution of Use:	This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice:	Avoid repeated freezing and thawing.
Storage:	4 °C/-20 °C
Storage Comment:	Store the antibody at 2 - 8 °C up to one month or (in aliquots) at -20 °C for longer.

### Images

